Literature DB >> 19454670

Hypercostimulation through 4-1BB distorts homeostasis of immune cells.

Seung-Woo Lee1, Shahram Salek-Ardakani, Robert S Mittler, Michael Croft.   

Abstract

The deleterious side effects associated with a recent clinical trial with anti-CD28 superagonist Abs have questioned the use of reagents to costimulatory molecules in human therapy. We now show that sustained signaling from an agonist Ab to 4-1BB, a member of the TNFR superfamily, results in detrimental effects on immune cell homeostasis. Repeated anti-4-1BB treatment during the reconstitution of hematopoietic cells in irradiated mice engrafted with bone marrow, or in mice infected with vaccinia virus, induced abnormal apoptosis of premature and immature B cells in the bone marrow, and led to peripheral B cell depletion. Inhibition of B cell development was indirect and due to costimulation of CD8 T cells and dependent on IFN-gamma. Moreover, anti-4-1BB also suppressed the development of NK and NKT cells, but in this case independently of T cells and IFN-gamma. The altered NK cell homeostasis resulted from activation-induced cell death triggered by anti-4-1BB. These results show that hypercostimulation elicits strong T cell immunity, but it can simultaneously distort immune homeostasis, suggesting that careful attention to activity, dose, and periodicity of treatment will be needed in any immunotherapeutic strategy with agonist Abs to costimulatory molecules.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19454670      PMCID: PMC2713069          DOI: 10.4049/jimmunol.0803241

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  45 in total

1.  Coordinate analysis of murine immune cell surface markers and intracellular phosphoproteins by flow cytometry.

Authors:  Peter O Krutzik; Matthew R Clutter; Garry P Nolan
Journal:  J Immunol       Date:  2005-08-15       Impact factor: 5.422

2.  Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412.

Authors:  Ganesh Suntharalingam; Meghan R Perry; Stephen Ward; Stephen J Brett; Andrew Castello-Cortes; Michael D Brunner; Nicki Panoskaltsis
Journal:  N Engl J Med       Date:  2006-08-14       Impact factor: 91.245

3.  Cytokine-mediated disruption of lymphocyte trafficking, hemopoiesis, and induction of lymphopenia, anemia, and thrombocytopenia in anti-CD137-treated mice.

Authors:  Liguo Niu; Simona Strahotin; Becker Hewes; Benyue Zhang; Yuanyuan Zhang; David Archer; Trent Spencer; Dirck Dillehay; Byoung Kwon; Lieping Chen; Anthony T Vella; Robert S Mittler
Journal:  J Immunol       Date:  2007-04-01       Impact factor: 5.422

Review 4.  Microenvironmental niches in the bone marrow required for B-cell development.

Authors:  Takashi Nagasawa
Journal:  Nat Rev Immunol       Date:  2006-02       Impact factor: 53.106

5.  Eradication of established tumors in mice by a combination antibody-based therapy.

Authors:  Tomoyasu Uno; Kazuyoshi Takeda; Yuko Kojima; Hirohisa Yoshizawa; Hisaya Akiba; Robert S Mittler; Fumitake Gejyo; Ko Okumura; Hideo Yagita; Mark J Smyth
Journal:  Nat Med       Date:  2006-05-07       Impact factor: 53.440

6.  Amelioration of mercury-induced autoimmunity by 4-1BB.

Authors:  Dass S Vinay; Jung D Kim; Byoung S Kwon
Journal:  J Immunol       Date:  2006-10-15       Impact factor: 5.422

7.  A consensus epitope prediction approach identifies the breadth of murine T(CD8+)-cell responses to vaccinia virus.

Authors:  Magdalini Moutaftsi; Bjoern Peters; Valerie Pasquetto; David C Tscharke; John Sidney; Huynh-Hoa Bui; Howard Grey; Alessandro Sette
Journal:  Nat Biotechnol       Date:  2006-06-11       Impact factor: 54.908

8.  The kinases aurora B and mTOR regulate the G1-S cell cycle progression of T lymphocytes.

Authors:  Jianxun Song; Shahram Salek-Ardakani; Takanori So; Michael Croft
Journal:  Nat Immunol       Date:  2006-11-26       Impact factor: 25.606

9.  TC-PTP-deficient bone marrow stromal cells fail to support normal B lymphopoiesis due to abnormal secretion of interferon-{gamma}.

Authors:  Annie Bourdeau; Nadia Dubé; Krista M Heinonen; Jean-François Théberge; Karen M Doody; Michel L Tremblay
Journal:  Blood       Date:  2007-01-18       Impact factor: 22.113

10.  Vaccinia virus-specific CD4+ T cell responses target a set of antigens largely distinct from those targeted by CD8+ T cell responses.

Authors:  Magdalini Moutaftsi; Huynh-Hoa Bui; Bjoern Peters; John Sidney; Shahram Salek-Ardakani; Carla Oseroff; Valerie Pasquetto; Shane Crotty; Michael Croft; Elliot J Lefkowitz; Howard Grey; Alessandro Sette
Journal:  J Immunol       Date:  2007-06-01       Impact factor: 5.422

View more
  26 in total

Review 1.  An RNA toolbox for cancer immunotherapy.

Authors:  Fernando Pastor; Pedro Berraondo; Iñaki Etxeberria; Josh Frederick; Ugur Sahin; Eli Gilboa; Ignacio Melero
Journal:  Nat Rev Drug Discov       Date:  2018-09-07       Impact factor: 84.694

2.  Targeting 4-1BB costimulation to disseminated tumor lesions with bi-specific oligonucleotide aptamers.

Authors:  Fernando Pastor; Despina Kolonias; James O McNamara; Eli Gilboa
Journal:  Mol Ther       Date:  2011-08-09       Impact factor: 11.454

Review 3.  Enhancing the safety of antibody-based immunomodulatory cancer therapy without compromising therapeutic benefit: Can we have our cake and eat it too?

Authors:  Joseph M Ryan; Jeffrey S Wasser; Adam J Adler; Anthony T Vella
Journal:  Expert Opin Biol Ther       Date:  2016-02-25       Impact factor: 4.388

4.  Chemotherapy followed by anti-CD137 mAb immunotherapy improves disease control in a mouse myeloma model.

Authors:  Camille Guillerey; Kyohei Nakamura; Andrea C Pichler; Deborah Barkauskas; Sophie Krumeich; Kimberley Stannard; Kim Miles; Heidi Harjunpää; Yuan Yu; Mika Casey; Alina I Doban; Mircea Lazar; Gunter Hartel; David Smith; Slavica Vuckovic; Michele Wl Teng; P Leif Bergsagel; Marta Chesi; Geoffrey R Hill; Ludovic Martinet; Mark J Smyth
Journal:  JCI Insight       Date:  2019-06-13

5.  Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function.

Authors:  Jessica Ann Hernandez-Chacon; Yufeng Li; Richard C Wu; Chantale Bernatchez; Yijun Wang; Jeffrey S Weber; Patrick Hwu; Laszlo G Radvanyi
Journal:  J Immunother       Date:  2011-04       Impact factor: 4.456

6.  SA-4-1BBL as the immunomodulatory component of a HPV-16 E7 protein based vaccine shows robust therapeutic efficacy in a mouse cervical cancer model.

Authors:  Rajesh K Sharma; Abhishek K Srivastava; Esma S Yolcu; Kathryn J MacLeod; Rich-Henry Schabowsky; Shravan Madireddi; Haval Shirwan
Journal:  Vaccine       Date:  2010-07-04       Impact factor: 3.641

Review 7.  SA-4-1BBL as a novel adjuvant for the development of therapeutic cancer vaccines.

Authors:  Rajesh K Sharma; Esma S Yolcu; Haval Shirwan
Journal:  Expert Rev Vaccines       Date:  2014-03       Impact factor: 5.217

8.  Anaphylaxis caused by repetitive doses of a GITR agonist monoclonal antibody in mice.

Authors:  Judith T Murphy; Andre P Burey; Amy M Beebe; Danling Gu; Leonard G Presta; Taha Merghoub; Jedd D Wolchok
Journal:  Blood       Date:  2014-02-20       Impact factor: 22.113

Review 9.  Advances in targeting cell surface signalling molecules for immune modulation.

Authors:  Sheng Yao; Yuwen Zhu; Lieping Chen
Journal:  Nat Rev Drug Discov       Date:  2013-02       Impact factor: 84.694

10.  IL-10 restricts activation-induced death of NK cells during acute murine cytomegalovirus infection.

Authors:  Maria A Stacey; Morgan Marsden; Eddie C Y Wang; Gavin W G Wilkinson; Ian R Humphreys
Journal:  J Immunol       Date:  2011-08-17       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.